Clinical trials: Thromboses, Venous
Peripheral Vascular Disease, Embolism and Thrombosis
Registry of AngioJet Use in the Peripheral Vascular System
The Registry involves the collection of information for research and educational purposes only on the use of AngioJet in the peripheral vascular system.
- Conditions
- Peripheral Vascular Disease, Embolism and Thrombosis, Venous Thrombosis
- Trial name
- PEARLII (NCT01086215)
- Where
- 36 sites in United States, Canada and 3 more
- Volunteers
- 500 people
- Sponsor
- Boston Scientific Corporation
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery
The primary objective was to compare the efficacy of once daily [q.d] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-HIP2 (NCT00721760)
- Testing
- Enoxaparin sodium, Semuloparin sodium
- Where
- 25 sites in United States, Argentina and 23 more
- Volunteers
- 1,003 people
- Sponsor
- Sanofi
Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort
Patients with active cancer are ~5-fold more likely to develop a venous thromboembolism (VTE) than those without. When VTE occurs, cancer patients carry an up to a 3-fold higher rate of thrombosis recurrence and ~twice the risk…
- Trial name
- OSCAR-US (NCT04979780)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
- Where
- United States
- Volunteers
- 3,708 people
- Sponsor
- Bayer
Thromboembolism
A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer
The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin.
- Trial name
- NCT05643885
- Where
- United States
- Volunteers
- 7,304 people
- Sponsor
- Pfizer
Retinal Vein Occlusion, Macular Edema
A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).
- Trial name
- NCT01918371
- Testing
- Anti-VEGF
- Where
- United States
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Allergan
Macular Edema, Retinal Vein Occlusion
Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201
The purpose of this non interventional retrospective study is to continue to collect data from patients following their completion of Protocol CLS 1003-201: "Safety and Efficacy of Suprachoroidal CLS-TA with Intravitreal…
- Trial name
- NCT02956330
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Clearside Biomedical, Inc.
Venous Thrombosis and Pulmonary Embolism
A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer
This study aims to collect patient reported outcomes and assess treatment satisfaction in active cancer patients treated with rivaroxaban for VTE (venous thromboembolism).
- Trial name
- COSIMO (NCT02742623)
- Testing
- Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- 10 sites in Australia, Belgium and 8 more
- Volunteers
- 528 people
- Sponsor
- Bayer
Venous Thromboembolism, Atopic Dermatitis
The Incidence of Venous Thromboembolism in Atopic Dermatitis
This study aims to investigate the incidence of venous thromboembolism in people who are diagnosed with atopic dermatitis.
- Conditions
- Venous Thromboembolism, Atopic Dermatitis, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- NCT04969653
- Testing
- Exposure of venous thromboembolism
- Where
- United Kingdom
- Volunteers
- 754,745 people
- Sponsor
- Momentum Data
Deep Vein Thrombosis, Post-thrombotic Syndrome
Elastic Compression Stockings for Prevention of Post-thrombotic Syndrome
Post thrombotic syndrome (PTS) is a frequent and burdensome complication of proximal deep-vein thrombosis.Therapeutic options for PTS are limited and mainly rely on its prevention.
- Trial name
- CELEST (NCT01578122)
- Testing
- 25mmHg ECS, 35 mmHg ECS
- Where
- 57 sites in France
- Volunteers
- 350 people
- Sponsor
- Laboratoires Innothera
Wet Age-related Macular Degeneration, Retinal Vein Occlusion
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg
- Conditions
- Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT03790852
- Testing
- KSI-301
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- Kodiak Sciences Inc
Venous Thromboembolism
An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism
This is an observational study in which only data will be collected from children with venous thromboembolism who are prescribed rivaroxaban or warfarin by their doctors.
- Trial name
- NCT06278051
- Testing
- Rivaroxaban granules for oral suspension, Warfarin
- Where
- 2 sites in Japan
- Volunteers
- 320 people
- Sponsor
- Bayer
Retinal Vein Occlusion
Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO
Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
- Trial name
- NCT02387788
- Testing
- AKB-9778
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Aerpio Therapeutics
Thrombosis, Venous
The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
The primary objective of this study is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism [VTE] (i.e., Pulmonary thromboembolism [PE] and Deep Vein Thrombosis [DVT])) and safety of…
- Trial name
- NCT00911157
- Testing
- Fondaparinux sodium, unfractionated heparin (UFH)
- Where
- 24 sites in Japan
- Volunteers
- 39 people
- Sponsor
- GlaxoSmithKline
Macular Edema
A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease
AURIGA is designed to collect data from routine clinical practice on the effectiveness and utilization of intravitreal aflibercept in the treatment of visual impairment due to diabetic macular edema (DME) or macula edema…
- Trial name
- AURIGA (NCT03161912)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- 11 sites in China, Egypt and 9 more
- Volunteers
- 2,481 people
- Sponsor
- Bayer
Venous Thrombosis
Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication
National, multicenter, prospective, observational, non-interventional study. The objective is to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects treated with VKA with issues in deep venous…
- Trial name
- SATORI (NCT01805544)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- France
- Volunteers
- 113 people
- Sponsor
- Bayer
Sepsis, Venous Thromboembolism
An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are Related
This is an observational study in which data already collected from people with venous thromboembolism (VTE) due to sepsis (blood poisoning) are studied.
- Conditions
- Sepsis, Venous Thromboembolism, Disseminated Intravascular Coagulation
- Trial name
- NCT06765681
- Testing
- Diagnosis of both VTE and sepsis
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Bayer
Macular Edema, Central Retinal Vein Occlusion
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at…
- Conditions
- Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
- Trial name
- COMINO (NCT04740931)
- Testing
- Faricimab, Aflibercept
- Where
- 194 sites in United States, Argentina and 20 more
- Volunteers
- 729 people
- Sponsor
- Hoffmann-La Roche
Thrombophlebitis Leg
Phlogenzym® in Patients With Acute Thrombophlebitis - Efficacy and Tolerance
Oral enzyme therapy in patients with acute superficial vein inflammation (thrombophlebitis) can serve as an additional treatment option besides standard therapy with compression stockings, common pain medication and physical…
- Trial name
- NCT03470337
- Testing
- Phlogenzym
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Mucos Pharma GmbH & Co. KG
Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD)
Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
This Phase 4, multicenter, randomized, double-masked clinical study evaluates the efficacy and safety of chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO) compared with routine anesthesia (topical proparacaine 0.5% combined…
- Conditions
- Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
- Trial name
- Quell (NCT07456826)
- Testing
- Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Harrow Inc
Venous Thromboembolism
Xarelto Regulatory Post-Marketing Surveillance
This study is to identify the following problems and questions with respect to the safety and effectiveness of Xarelto in comparison with other pharmacologic agents in the prophylaxis of venous thromboembolism (VTE) in a large…
- Trial name
- NCT01029743
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)
- Where
- South Korea
- Volunteers
- 3,388 people
- Sponsor
- Bayer